Satsuma Pharmaceuticalsincis A Biopharmaceutical Company Based In Durhamnorth Carolinafocused On Developing Innovative Treatments For Debilitating Conditionsparticularly Migrainesfounded In 2016It Operates As A Subsidiary Of Shin Nippon Biomedical Laboratoriesltdsince June 2023 The Company Is Dedicated To Creating Novel Therapeutic Productswith Its Flagship Offering Being Sts101This Drug Device Combination Features A Proprietary Dry Powder Formulation Of Dihydroergotamine Mesylatedesigned For Self Administration Through Pre Filledsingle Use Nasal Delivery Devicessatsuma Also Utilizes The Smartsimple Mucoadhesive Release Technologyplatform To Enhance Treatment Efficacy And Administrationtheir Products Aim To Provide Relief For Adults Suffering From Migrainesincluding Those With Or Without Aura
